| Oct 29 |
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
|
| Oct 17 |
Nektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemia
|
| Oct 17 |
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
|
| Sep 30 |
Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset
|
| Sep 25 |
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
|
| Sep 11 |
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
|
| Aug 13 |
What Makes Nektar (NKTR) a New Buy Stock
|
| Aug 10 |
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
|
| Aug 10 |
Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 9 |
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
|
